Houston patients are struggling to find Ozempic as the popularity of weight loss drugs skyrockets on social media

HOUSTON – The drug Semaglutide was initially marketed under the name Ozempic to treat type 2 diabetes. Last year, Semaglutide was approved by the FDA to be used for weight loss under the name Wegovy.

Social media has nicknamed them “skinny pens” because they help people lose significant weight quickly, which led to the popularity and shortage of both Ozempic and Wegovy.

The drugmaker Novo Nordisk confirms it is struggling to keep up with demand and Houston patients like Lauren Luman say it doesn’t know what it will do.

“I contacted my doctor again to let them know that I was still experiencing that deficiency. At that point they could give me some more samples, but they said, ‘We’re not sure how long we’ll continue to get the samples available. to have,” said Luman.

Ozempic helped Luman lose weight and control her blood sugar. Now she says she gets the same answer at every pharmacy she visits.

“It’s been weeks or months since they’ve had anything,” Luman said.

Endocrinologists have said they are frustrated that patients can’t find their medication. Endocrinologist Dr. However, Disha Narang suggests that there is a need for successful weight loss drugs in the market.

“Our nation is, you know, there’s also an epidemic of obesity and we need to treat the obesity to prevent diabetes in the first place,” said Dr. Narang.

Doctors are doing nothing wrong by prescribing Ozempic for obesity. According to the FDA, healthcare professionals can choose to prescribe drugs off-label when it is medically appropriate to do so.

“Its intended use is that it’s an antidiabetic prescription,” Luman said. “So if people are just using it for weight loss I feel maybe they should step back and give the people who have type 2 diabetes and really need it their A1C the option to get this prescription .”

According to one study, weight loss may return once the patient stops taking it.

Copyright 2023 by KPRC Click2Houston – All rights reserved.

Leave a Comment